Roche presents Phase III data on Rituxan

Roche (SWX:ROCZ) presented interim data from treatment-naive patients with non-Hodgkins lymphoma (NHL) showing

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE